• KOLs Community
    • Squamous
    • Squamous Cell
    • Robert Louis Ferris
    • Robert Louis Ferris

      Robert Louis Ferris

      Department of Otolaryngology, University of Pittsburgh Cancer Institute, Pittsburgh, PA, USA | Department of Otolaryngology, Hillman Cancer Institute, University of ...



      KOL Resume for Robert Louis Ferris


      Department of Otolaryngology, University of Pittsburgh Cancer Institute, Pittsburgh, PA, USA

      University of Pittsburgh Medical Center and University of Pittsburgh Cancer Institute, Pittsburgh, PA;

      Cancer Immunology and Immunotherapy Program, UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania.


      Department of Immunology, University of Pittsburgh, Pittsburgh, PA USA

      UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, Pennsylvania, United States of America

      University of Pittsburgh Hillman Cancer Center

      Magee-Womens Research Institute, Pittsburgh, Pennsylvania


      Department of Otolaryngology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15261

      UPMC Hillman Cancer Center, Pittsburgh, PA 15213, USA;,

      Tumor Microenvironment Center, Hillman Cancer Center, University of Pittsburgh, PA, USA

      University of Pittsburgh Medical Center Hillman Cancer Center, Pittsburgh, PA.



      Robert Louis Ferris: Influence Statistics

      Sample of concepts for which Robert Louis Ferris is among the top experts in the world.
      Concept World rank
      pet outcome logrank #1
      peripheral cd8 cells #1
      tumor cells attraction #1
      logrank hpv status #1
      intermediaterisk lowrisk #1
      b16f10 melanoma tumors #1
      progressionfree survival rate #1
      mhpv #1
      peptides cell recognition #1
      opscc total #1
      level 1 500 #1
      qrtpcr pathology #1
      investigators choice #1
      treated hnscc #1
      sbrt rscchn #1
      abt869 cytotoxicity #1
      reviewdiscussion #1
      systemic immune dysfunction #1
      pax8glis3 #1
      hpv16 dna head #1
      ki67 proliferation ordering #1
      pva strongest correlation #1
      homologous recombination gain #1
      sbrt±cetuximab rscchn #1
      suppressive function tim3 #1
      ps727stat1 #1
      laryngeal toxicity #1
      controlled window #1
      ecs detection #1
      hros pfdr 00030 #1
      negative scchn #1
      cognate mutant tumors #1
      ccr7 thiazoles regulation #1
      analysis 220 ptc #1
      ccr7 receptors scchn #1
      mechanism tlr3mediated apoptosis #1
      dysphonia acss #1
      paracrine activation ccr7 #1
      sting activation maturation #1
      sema4a gc tilbs #1
      ajcc8 carcinoma #1
      glossectomy specimen tbm #1
      biomarker modulation erlotinib #1
      acss risk factors #1
      response rates ici #1
      95 posttreatment hpv16 #1
      multiplexed qrtpcr detection #1
      hnscc pdx #1
      rtinduced pdl1 upregulation #1


      Prominent publications by Robert Louis Ferris

      KOL-Index: 25936

      BACKGROUND: Patients with platinum-refractory recurrent or metastatic squamous cell carcinoma of the head and neck have few treatment options and poor prognosis. Nivolumab significantly improved survival of this patient population when compared with standard single-agent therapy of investigator's choice in Checkmate 141; here we report the effect of nivolumab on patient-reported outcomes (PROs).

      METHODS: CheckMate 141 was a randomised, open-label, phase 3 trial in patients with recurrent ...

      Known for Nivolumab Patients | Cell Carcinoma | Checkmate 141 | Investigators Choice | Metastatic Squamous
      KOL-Index: 21644

      IMPORTANCE: At many institutions, computed tomography with iodinated intravenous contrast medium is the preferred imaging modality for staging of the neck in squamous cell carcinoma of the head and neck. However, few studies have specifically assessed the diagnostic accuracy of computed tomography for determining the presence or absence of extracapsular spread (ECS).

      OBJECTIVE: To determine the accuracy of modern, contrast-enhanced, multidetector computed tomography in the diagnosis of ...

      Known for Computed Tomography | Squamous Cell Carcinoma | Extracapsular Spread | Head Neck | Presence Ecs
      KOL-Index: 19185

      BACKGROUND: Targeting the programmed cell death protein 1 (PD-1)/programmed cell death ligand 1 (PD-L1) axis has demonstrated clinical benefit in recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC). Combining immunotherapies targeting PD-L1 and cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) has shown evidence of additive activity in several tumor types. This phase III study evaluated the efficacy of durvalumab (an anti-PD-L1 monoclonal antibody) or durvalumab ...

      Known for Durvalumab Tremelimumab | Squamous Cell | Monoclonal Antibodies | Metastatic Head | Phase Iii
      KOL-Index: 17766

      PURPOSE: Tumor antigen-specific monoclonal antibodies (mAb) block oncogenic signaling and induce Fcγ receptor (FcγR)-mediated cytotoxicity. However, the role of CD8(+) CTL and FcγR in initiating innate and adaptive immune responses in mAb-treated human patients with cancer is still emerging.

      EXPERIMENTAL DESIGN: FcγRIIIa codon 158 polymorphism was correlated with survival in 107 cetuximab-treated patients with head and neck cancer (HNC). Flow cytometry was carried out to quantify EGF ...

      Known for Tumor Antigen | Dendritic Cells | Natural Killer | Hnc Cetuximab | Neck Cancer
      KOL-Index: 17138

      BACKGROUND: Patients with recurrent or metastatic squamous-cell carcinoma of the head and neck after platinum chemotherapy have a very poor prognosis and limited therapeutic options. Nivolumab, an anti-programmed death 1 (PD-1) monoclonal antibody, was assessed as treatment for this condition.

      METHODS: In this randomized, open-label, phase 3 trial, we assigned, in a 2:1 ratio, 361 patients with recurrent squamous-cell carcinoma of the head and neck whose disease had progressed within 6 ...

      Known for Standard Therapy | Cell Carcinoma | Patients Nivolumab | Neck Treatment | Recurrent Squamous
      KOL-Index: 15195

      PURPOSE: Two modern methods of reirradiation, intensity modulated radiation therapy (IMRT) and stereotactic body radiation therapy (SBRT), are established for patients with recurrent or second primary squamous cell carcinoma of the head and neck (rSCCHN). We performed a retrospective multi-institutional analysis to compare methods.

      METHODS AND MATERIALS: Data from patients with unresectable rSCCHN previously irradiated to ≥40 Gy who underwent reirradiation with IMRT or SBRT were ...

      Known for Primary Head | Imrt Sbrt | Neck Cancer | Local Neoplasms | Rpa Class
      KOL-Index: 15076

      BACKGROUND: The authors hypothesized that histogenetic classification of salivary duct carcinoma (SDC) could account for de novo tumors and those with morphologic or molecular evidence (pleomorphic adenoma gene 1 [PLAG1], high-mobility group AT hook 2 [HMGA2] rearrangement, amplification) of pleomorphic adenoma (PA).

      METHODS: SDCs (n = 66) were reviewed for morphologic evidence of PA. PLAG1 and HMGA2 alterations were detected by fluorescence in situ hybridization (FISH). PLAG1-positive ...

      Known for Pleomorphic Adenoma | Salivary Duct Carcinoma | Situ Hybridization | Morphologic Evidence Pa | Plag1 Hmga2
      KOL-Index: 15048

      BACKGROUND: Fine-needle aspiration (FNA) cytology is a common approach to evaluating thyroid nodules, although 20% to 30% of FNAs have indeterminate cytology, which hampers the appropriate management of these patients. Follicular (or oncocytic) neoplasm/suspicious for a follicular (or oncocytic) neoplasm (FN/SFN) is a common indeterminate diagnosis with a cancer risk of approximately 15% to 30%. In this study, the authors tested whether the most complete next-generation sequencing (NGS) ...

      Known for Thyroid Nodules | Follicular Neoplasm | Thyroseq V2 | Fineneedle Carcinoma Carcinoma | Oxyphilic Biopsy
      KOL-Index: 15042

      Immunotherapy with the EGFR-specific mAb cetuximab is clinically effective in 10–20% of patients with squamous cell carcinoma of the head and neck (SCCHN). Little information is available about the mechanism(s) underlying patients’ differential clinical response to cetuximab-based immunotherapy, although this information may contribute to optimizing the design of cetuximab-based immunotherapy. Our understanding of these mechanisms would benefit from the characterization of the variables ...

      Known for Nk Cell | Cetuximab Mediated | Egfr Expression | Monoclonal Antibodies | Genetic Receptors
      KOL-Index: 15027

      PURPOSE: Locally recurrent head and neck squamous cell carcinoma can be treated with curative intent by surgical salvage or reirradiation with or without chemotherapy. We have previously demonstrated the feasibility and safety of stereotactic body reirradiation at our institution; however, efficacy has been unsatisfactory. Based on the successful combination of cetuximab with radiotherapy in locally-advanced squamous cell carcinoma of the head and neck, we compared stereotactic body ...

      Known for Stereotactic Body Radiotherapy | Squamous Cell | Head Neck | Concurrent Cetuximab | Antibodies Monoclonal Antibodies
      KOL-Index: 14705

      Importance: Approximately 20% of fine-needle aspirations (FNA) of thyroid nodules have indeterminate cytology, most frequently Bethesda category III or IV. Diagnostic surgeries can be avoided for these patients if the nodules are reliably diagnosed as benign without surgery.

      Objective: To determine the diagnostic accuracy of a multigene classifier (GC) test (ThyroSeq v3) for cytologically indeterminate thyroid nodules.

      Design, Setting, and Participants: Prospective, blinded cohort study ...

      Known for Indeterminate Cytology | Thyroid Nodules | Bethesda Iii | Tumor Biopsy | Multigene Genomic Classifier
      KOL-Index: 14584

      PURPOSE: Cetuximab, which modulates immune responses, may affect the efficacy of subsequent immunotherapy. Here, we assessed outcomes with nivolumab, by prior cetuximab exposure, in patients with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN) who had experienced progression within 6 months of platinum-containing chemotherapy.

      PATIENTS AND METHODS: In the randomized, open-label, phase III CheckMate 141 trial, patients were randomized 2:1 to nivolumab 3 ...

      Known for Prior Cetuximab | Nivolumab Patients | Squamous Cell | Head Neck | Antineoplastic Agents
      KOL-Index: 14193

      BACKGROUND: Extracapsular spread (ECS) in cervical lymph node metastases from head and neck squamous cell carcinoma (SCC) is regarded as an adverse prognostic factor and is often used to select patients who may benefit from adjuvant therapy. The prognostic value of ECS was evaluated for patients with oropharyngeal SCC (OPC; with known p16/human papillomavirus [HPV] status) and for patients with SCC of the oral cavity (OCC).

      METHODS: Disease-specific survival (DSS) was assessed among SCC ...

      Known for Extracapsular Spread | Neck Carcinoma | Papillomavirus Status | Ecs Patients | 16 Humans
      KOL-Index: 14103

      IMPORTANCE: Positive margins are associated with poor prognosis among patients with oral tongue squamous cell carcinoma (SCC). However, wide variation exists in the margin sampling technique.

      OBJECTIVE: To determine the effect of the margin sampling technique on local recurrence (LR) in patients with stage I or II oral tongue SCC.

      DESIGN, SETTING, AND PARTICIPANTS: A retrospective study was conducted from January 1, 1986, to December 31, 2012, in 5 tertiary care centers following tumor ...

      Known for Tumor Bed | Local Control | Oral Tongue | Positive Margins | Squamous Cell
      KOL-Index: 14073

      OBJECTIVE/HYPOTHESIS: The utility of elective neck dissection in the management of patients with oral cavity and oropharyngeal cancer who present without neck metastases remains controversial. The study addressed the question of whether elective neck dissection improves regional control and survival in patients with squamous cell carcinoma of the oral cavity and oropharynx presenting with T1/T2 node-negative disease.

      STUDY DESIGN: A nonrandomized, uncontrolled retrospective chart ...

      Known for Elective Neck Dissection | Oral Cavity | Squamous Cell Carcinoma | Regional Control | Patients Neck

      Key People For Squamous Cell

      Top KOLs in the world
      Ahmedin M Jemal
      united states breast cancer addis ababa
      Freddie Ian Bray
      cancer incidence nordic countries mortality rates
      Jacques Ferlay
      cancer incidence global burden latin america
      Rebecca L Siegel
      united states colorectal cancer incidence rates
      William H Westra
      human papillomavirus squamous cell head neck
      Arlene A Forastiere
      neck cancer squamous cell radiation therapy

      Robert Louis Ferris:Expert Impact

      Concepts for whichRobert Louis Ferrishas direct influence:Squamous cell,  Neck cancer,  Head neck,  Cell carcinoma,  Squamous cell carcinoma,  Neck neoplasms humans,  Human papillomavirus,  Neck squamous.

      Robert Louis Ferris:KOL impact

      Concepts related to the work of other authors for whichfor which Robert Louis Ferris has influence:Squamous cell,  Head neck,  Thyroid nodules,  Tumor microenvironment,  Human papillomavirus,  Cancer immunotherapy,  Immune checkpoint inhibitors.



      Is this your profile? manage_accounts Claim your profile content_copy Copy URL code Embed Link to your profile

      Department of Otolaryngology, University of Pittsburgh Cancer Institute, Pittsburgh, PA, USA | Department of Otolaryngology, Hillman Cancer Institute, University of Pittsburgh, Pittsburgh, PA 15213, USA;, ferrrl@upmc.edu | Department of Otolaryngolog

    Download on the App StoreGet it on Google Play

    Copyright © 2023 - KOL means Key Opinion Leaders .

    KOL does not provide medical advice, diagnosis or treatment.